US OptionsDetailed Quotes
OMGA241220C5000
- 0.05
- 0.000.00%
15min DelayTrading Nov 5 14:47 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume12 Open Interest5.00Strike Price0.00Turnover2080.60%IV526.55%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1586Delta0.2606Gamma16.13Leverage Ratio-0.0500Theta0.0000Rho2.56Eff Leverage0.0001Vega
Omega Therapeutics Stock Discussion
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer
Ampersand's AND™ Platform will be used to identify programmed biologics for the
treatment of obesity-related targets
Montai's CONECTA™ AI platform will be used to identify small molecules directed to a
potential Non-Small Cell Lung Cancer-related target
Collaborations will leverage Pfizer's deep expertise in early di...
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
Positive
Phase 1 MYCHELANGELO trial showed 50% disease control rate in HCC patients
Reduced net loss to $16.4M in Q3 2024 from $22.2M in Q3 2023
R&D expenses decreased by $3.7M compared to Q3 2023
G&A expenses reduced by $1.0M compared to Q3 2023
Ongoing collaboration with Novo Nor...
Might buy some tomorrow if price goes below $1 again.
Very nice moves.
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
Omega Therapeutics (Nasdaq: OMGA) has published preclinical data for OTX-2002, their epigenomic controller targeting the MYC gene in hepatocellular carcinoma (HCC), in Nature Communications. The study demonstrates OTX-2002's ability to downregulate MYC expression and inhibit tumor growth in HCC models, both as a monotherapy and in combination wi...
NEWS
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
Investors Rethink Rate Cut Bets
US equities ended Friday slightly higher, but gains weren't enough to keep major indices in the green in the first trading week of the year. The stock market ended their nine-week winning streak as investors rethink bets of aggressive interest rate cuts this year amid signs of continued strength in the labor market.
The $S&P 500 Index (.SPX.US)$ rose 0.2% to close at 4,697.24 Friday, while the $Nasdaq Composite Index (.IXIC.US)$ rose less...
No comment yet